Angiogenesis inhibitors in the treatment of non-small-cell lung cancer (NSCLC)

被引：2
|
作者：
Carcereny Costa, Enric [1 ]
Vinolas Segarra, Nuria [1 ]
Gascon Vilaplana, Pere [1 ]
机构：
[1] Univ Barcelona, IDIBAPS, Med Oncol Serv, Hosp Clin ICMHO, ES-08036 Barcelona, Spain
来源：
CLINICAL & TRANSLATIONAL ONCOLOGY | 2008年 / 10卷 / 04期
关键词：
angiogenesis; inhibitors; non-small-cell lung cancer; treatment;
D O I：
10.1007/s12094-008-0182-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Lung cancer is a leading cause of death worldwide and, although some progress has been made in its treatment, the results remain poor. Better knowledge in tumour biology has allowed us to design anti-target drugs and incorporate them in the treatment of non-small-cell lung cancer (NSCLC). One of the most widely used targeted approaches in this type of tumour has been the inhibition of angiogenesis. Several strategies blocking the VEGF pathway, either at the ligand or recepor level, have been studied and developed. In this review, we present an up-to-date analysis of the current inhibitors of angiogenesis in the treatment of NSCLC.
引用
收藏
页码：198 / 203
页数：6
相关论文
共 50 条
  • [1] Angiogenesis inhibitors in the treatment of non-small-cell lung cancer (NSCLC)
    Enric Carcereny Costa
    Núria Viñolas Segarra
    Pere Gascón Vilaplana
    [J]. Clinical and Translational Oncology, 2008, 10
  • [2] First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with ImmuneCheckpoint Inhibitors
    Bylicki, Olivier
    Barazzutti, Helene
    Paleiron, Nicolas
    Margery, Jacques
    Assie, Jean-Baptiste
    Chouaid, Christos
    [J]. BIODRUGS, 2019, 33 (02) : 159 - 171
  • [3] First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors
    Olivier Bylicki
    Helene Barazzutti
    Nicolas Paleiron
    Jacques Margery
    Jean-Baptiste Assié
    Christos Chouaïd
    [J]. BioDrugs, 2019, 33 : 159 - 171
  • [4] Angiogenesis inhibitors in the treatment of small cell and non-small cell lung cancer
    Blackhall, FH
    Shepherd, FA
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2004, 18 (05) : 1121 - +
  • [5] Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC)
    Tiseo, M.
    Bartolotti, M.
    Gelsomino, F.
    Bordi, P.
    [J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2010, 4 : 81 - 98
  • [6] Review of economic analyses of treatment for non-small-cell lung cancer (NSCLC)
    Vergnenegre, Alain
    Chouaid, Christos
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2018, 18 (05) : 519 - 528
  • [7] An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer
    Pilotto, Sara
    Novello, Silvia
    Peretti, Umberto
    Kinspergher, Stefania
    Ciuffreda, Ludovica
    Milella, Michele
    Carbognin, Luisa
    Vavala, Tiziana
    Ferrara, Roberto
    Caccese, Mario
    Tortora, Giampaolo
    Bria, Emilio
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2015, 24 (09) : 1143 - 1161
  • [8] The Story of Angiogenesis Inhibitors in Non-small-cell Lung Cancer: The Past, Present, and Future
    Shukla, Nikhil Atul
    Yan, Melissa Noela
    Hanna, Nasser
    [J]. CLINICAL LUNG CANCER, 2020, 21 (04) : 308 - 313
  • [9] Cetuximab in advanced non-small-cell lung cancer (NSCLC)
    Pirker, Robert
    [J]. LUNG CANCER, 2012, 77 : S13 - S14
  • [10] RET Inhibitors in Non-Small-Cell Lung Cancer
    Cascetta, Priscilla
    Sforza, Vincenzo
    Manzo, Anna
    Carillio, Guido
    Palumbo, Giuliano
    Esposito, Giovanna
    Montanino, Agnese
    Costanzo, Raffaele
    Sandomenico, Claudia
    De Cecio, Rossella
    Piccirillo, Maria Carmela
    La Manna, Carmine
    Totaro, Giuseppe
    Muto, Paolo
    Picone, Carmine
    Bianco, Roberto
    Normanno, Nicola
    Morabito, Alessandro
    [J]. CANCERS, 2021, 13 (17)
12345